Second generation antipsychotics (SGAs) are effective options in the treatment of
schizophrenia and mood disorders, each with characteristic efficacy and safety features. In …

Abstract Objectives The 2018 Canadian Network for Mood and Anxiety Treatments
(CANMAT) and International Society for Bipolar Disorders (ISBD) guidelines provided …

Background Compulsive exercise has been recognized as a highly prevalent symptom in
eating disorders (ED) for over 100 years and is associated with poor short-term and long …

Background Pharmacological augmentation is a recommended strategy for patients with
treatment-resistant depression. A range of guidelines provide advice on treatment selection …

BackgroundMost people with bipolar disorder spend a significant percentage of their lifetime
experiencing either subsyndromal depressive symptoms or major depressive episodes …

This paper focuses on depression that precedes an onset of manifest bipolar disorder as
early stage bipolar disorder. First, we review how to pragmatically identify the clinical …

Objective In this paper, we aimed at reviewing evidence‐based treatment options for bipolar
mania and proposed tentative evidence‐based clinical suggestions regarding the …

Several mood-stabilizing atypical antipsychotics and antidepressants weakly block
serotonin (5-HT) receptor type-7 (5-HT7R); however, the contributions of 5-HT7R …

Objectives This systematic review aimed at providing a critical, comprehensive synthesis of
international guidelines' recommendations on the long‐term treatment of bipolar disorder …

Mood disorders remain a major public health concern worldwide. Monoaminergic
hypotheses of pathophysiology of bipolar and major depressive disorders have led to the …